Plain-English translation of NCT05155046 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new imaging scan called can help doctors see how well radiation therapy (SBRT) is working for prostate cancer. The scan uses a special radioactive tracer that binds to cancer cells, making them light up on imaging. Researchers want to know if this scan can detect cancer that comes back earlier and more accurately than standard imaging methods.
After radiation therapy for prostate cancer, doctors usually wait to see if PSA levels (a blood marker) start rising to know if the cancer is coming back. By that time, the cancer may have already regrown. This new imaging method might be able to spot early signs of cancer returning before PSA levels rise, allowing doctors to treat it sooner with potentially better results.
You likely qualify if…
You likely don't qualify if…
You will receive stereotactic body radiation therapy to your prostate as planned. In addition, you will have the new imaging scan done before your radiation treatment and again after treatment to see how well it worked. The scan involves receiving an injection of the radioactive tracer and then lying still while a PET/CT scanner takes pictures. You will also continue to have standard MRI imaging and PSA blood tests as part of your routine care.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States